FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPRO	VAL							
	OMB Number:	3235-0287							
l	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	nd Address of R JOSHU	<u>V</u>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]									(Check all applic		r 10% (give title Othe						
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE							3. Date of Earliest Transaction (Month/Day/Year) 07/13/2016									1: 110		below)		
(Street) BOSTON MA 02210					-   4. I' -	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)      X Form filed by One Reporting Person      Form filed by More than One Reporting Person					
(City)	(Si		(Zip)																	
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y					tion	2A. E Exec if any	Deeme	ed	3. Transaction Code (Instr. 8)		4. Securities Acquired (A)		(A) or	5. Amou Securitie Benefici Owned F		nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	1	Reported Transact Instr. 3	tion(s)			Instr. 4)	
Common	Stock			07/13/2	2016	16			M		6,500	A	\$36.3	5.3 274		,725	D			
Common Stock 07/13/201						16			S <sup>(1)</sup>		4,700	D	\$88.47	2)(3)	270,0		D			
Common Stock 07/13/202					2016	16			S <sup>(1)</sup>		1,800	D	\$89.680	2)(4)	268,22		D			
Common Stock															13,	,286	I	4	401k	
Common Stock															122	2,700	I	1	Common Stock Held In Trust	
		Т	able II								posed of				ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transa Code ( 8)	ection	5. Number of			Exerc	isable and	7. Title an Amount Securitie Underlyin	nd of s ng e Security	8. Pi Deri Seci	ivative curity str. 5)	9. Number derivative Securities Securities Owned Following Reported Transactio (Instr. 4)	Ow For Dire or I (I) (	nership	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares	1						
Stock Option (Right to Buy)	\$36.3	07/13/2016			M			6,500	(5)	)	01/23/2017	Common Stock	6,500	\$(	0.00	170,500	0	D		

- 1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- 2. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 3. Open market sales reported on this line occurred at a weighted average price of \$88.47 (range \$87.98 to \$88.84).
- 4. Open market sales reported on this line occurred at a weighted average price of \$89.68 (range \$89.00 to \$89.91).
- 5. Fully vested.

## Remarks:

Omar White, Attorney-In-Fact 07/15/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.